Home > Insider Trading > Filing (0001628280-25-026581)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1104506	Insmed Inc	INSM	Pharmaceutical Preparations (2834)	541972729

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1796960	M.d. Martina Flammer	700 Us Highway 202/206 Bridgewater NJ 08807	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-05-15	6,508	$0.00	96,521	No	4	A	Direct
Common Stock	Disposition	2025-05-15	9,925	$65.47	86,596	No	4	S	Direct
Common Stock	Disposition	2025-05-16	1,799	$67.53	84,797	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2025-05-15	31,610	$0.00	31,610	$67.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
31,610		2035-05-15	No	4	A	Direct

Footnotes

Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
Each RSU was granted on May 15, 2025 for no consideration.
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
This is the weighted average sales price representing 9,925 shares sold at prices ranging from $65.32 to $65.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.